Antex Biologics (ANTX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Antex Biologics (ANTX)

ANTX 1.090

-2.7%

Nov 19 3:56 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sanjay Jain who wrote (741)	3/5/1998 11:38:00 AM
From: John R Resseger	Read Replies (1) of 1476

Signal Transduction Antex scientists create the Campylobactor vaccine using the company's Nutriment Signal Transduction (NST) technology to generate Campylobacter cells in the laboratory that are as virulent as if they were isolated from an infected person. They accomplish this by identifying the specific nutriments (i.e., broth additives and aeration levels) required by the bacteria to express, via signal transduction, various virulent factors. Antex's oral Helicobacter pylori vaccine, also made from whole killed cells grown with the NST system, is in Phase I trials. Target indications include gastritis, peptic ulcers and gastric carcinoma. In preclinical studies, the vaccine demonstrated the ability to protect animals from disease and clear the bacteria from sick animals. . Antex is developing the Helicobacter and Campylobacter vaccines under a strategic alliance formed two years ago with SmithKline Beecham to develop and commercialize bacterial vaccines based on Antex's proprietary technologies for respiratory, gastrointestinal and sexually transmitted diseases.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next